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The aim of radiotherapy is to eradicate cancer, while at the 
same time minimizing the side effects. Although important 
improvements in imaging and radiotherapy techniques have 
enabled better target definitions and radiotherapy delivery, 
normal tissues are always exposed to radiation to some 
degree. Side effects thus still occur, but their variable 
degree, even when corrected for dosimetric characteristics, 
suggests that common genetic variants may play a role.  
However, similar to other human traits, radiosensitivity is 
considered to be a complex polygenic phenotype determined 
by the interaction of multiple loci. 
Identifying these genetic markers will further enable 
precision radiotherapy in which the optimal treatment plan 
will take into account the genetic pre-disposition to toxicity 
(and of the tumour). It should not be assumed that all of the 
phenotypic variation is due to germ line genetic variation, 
but that that epigenetic changes (inherited and acquired) 
could also be important, including variants in mitochondrial 
DNA. 
In response to the lack of success of candidate gene SNP 
studies in small studies, the focus of radiogenomics has 
shifted towards GWAS and big data research within 
international networks (1). At the same time, effort was 
made to establish standardized methods for reporting on 
radiogenomics (2). In recent years, remarkable progress has 
been made in the field of radiogenomics, of which some 
examples are cited. 
Single nucleotide polymorphism genotypes were determined 
in female breast cancer patients from the RAPPER study, 
showing that patients with a high polygenic predisposition to 
breast cancer do not have an increased risk of radiotherapy 
toxicity, but that individual variants may increase risk (3). 
Identifying SNPs in oxidative stress-related genes associated 
with risk of late toxicities in breast cancer patients receiving 
radiation therapy, a variant allele in the base excision repair 
gene XRCC1 was found that could be used in combination 
with additional variants to predict late toxicities (4).  
A GWAS study in 1742 prostate cancer patients treated with 
external beam radiotherapy identified the TANC1 locus (that 
has a role in regenerating damaged muscle) to be of 
significant importance in the development of late radiation-
induced damage (5). It is expected that these and other 
improvements in genotyping together with better 
phenotyping of patients will be incorporated in treatment 
planning, decision support systems and drug development to 
increase the therapeutic ratio of radiotherapy. 
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Combinaison of radiotherapy and immunomodulatory approaches 
is an emerging field. Beside the concurrent inhibition of immune 
checkpoints inhibitors, the association of anti tumor vaccines is a 
way to stimulate specific anti tumor immunity during 
radiotherapy.  Here, we report an extremely effective 
combination of local irradiation (IR) and Shiga Toxin B (STxB)-
based human papillomavirus (HPV) vaccination for the treatment 
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of HPV-associated head and neck squamous cell carcinoma 
(HNSCC). The efficacy of the irradiation and vaccine association 
was tested using a model of HNSCC obtained by grafting TC-
1/luciferase cells at a submucosal site of the inner lip of 
immunocompetent mice. Irradiation and the STxB-E7 vaccine 
acted synergistically with both single and fractionated irradiation 
schemes, resulting in complete tumor clearance in the majority of 
the treated mice. A dose threshold of 7.5 Gy was required to 
elicit the dramatic antitumor response. The combined treatment 
induced high levels of tumor-infiltrating, antigen-specific CD8(+) T 
cells, which were required to trigger the antitumor activity. 
Treatment with STxB-E7 and irradiation induced CD8(+) T-cell 
memory, which was sufficient to exert complete antitumor 
responses in both local recurrences and distant metastases. We 
also report for the first time that a combination therapy based on 
local irradiation and vaccination induces an increased pericyte 
coverage (as shown by αSMA and NG2 staining) and ICAM-1 
expression on vessels. This was associated with enhanced 
intratumor vascular permeability that correlated with the 
antitumor response, suggesting that the combination therapy 
could also act through an increased accessibility for immune cells. 
The combination strategy proposed here offers a promising 
approach that could potentially be transferred into clinical trials. 
The implementation of selective immunomodulatory approaches 
during the treatment of HPV positive tumors could eventually lead 
to increase anti tumor efficacy with favorable tumor versus 
normal tissue differential effect. 
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Radiation therapy is an ever changing discipline and 
technology. It has made unprecedented improvements with 
the incorporation of concurrent chemotherapy regimens 
which translated into local control and survival gains. The 
improvements of beam delivery techniques have led to 
decrease in morbidity following treatment. We are now 
facing an important wave of changing concepts which 
profoundly impact our understanding of the basic  
mechanistic of oncology which have had profound 
consequences on the perception of the biology of response to 
radiotherapy having both consequences for tumor and normal 
tissues. Interestingly these changes do not replace former 
concepts but rather contribute to broaden the scope of 
radiation biology. Direct radiation induced cell kill of tumor 
clonogens has now to be integrated within the concept of 
microenvironment. The overwhelming contribution of tumor 
hypoxia remains un disputed but the  concept of  micro 
environment by itself  now implies the contribution of several 
cellular compartments which are shown to contribute to both 
tumor response and the generation of normal tissue damage. 
These findings have paved the way for a new generation of 
combination of clinical trials which are now emerging. The 
possibility that immune modulation during the course of 
radiotherapy could not only have impact on local control but 
also on distant  disease is a fascinating paradigm. Technology 
for treatment and imaging have in parallel considerably 
evolved, leading to increased precision and targeting 
possibilities widening the use of stereotactic radiotherapy 
which constitutes a major change for the management of 
primary and secondary tumors. Routine integration of 
biomarkers in our tumor rounds such as HPV status for head 
and neck and 1p19q for brain tumors are examples of the 
integration of the concept of precision medecine into 
radiotherapy and other examples should follow. 
Functional imaging and the latest developments of image 
texture analysis will contribute to increase the level of 
precision of our treatments, define the areas at risk for 
relapse but these images  might also contains valuable 
biological information. Practical examples of clinical trials 
using novel technologies (nanoparticles), biomarkers 
selection and oligometastatic disease, will be used to present 
the practical integration and the challenges represented by 
these novel concepts into the clinic. 
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Purpose: Additive manufacturing is becoming of interest in 
Radiotherapy especially for bolus creation. This study aimed 
to develop an in-house procedure to print photon bolus 
created with the treatment planning system (TPS) using small 
sized printers, cost effective, and logistically easy to 
implement in RT departments.  
Material/methods: A fused deposition modeling (FDM) printer 
with a heated bed plate (Rova3D, Ordsolutions, Ontario, 
Canada), was used together with Poly-Lactic-Acid (PLA) 
material. Using as TPS  Eclipse™ version 13 (Varian Medical 
Systems, Palo Alto, California) a plan was created on a 
Rando head phantom  CT scan and a “digital” bolus created 
in the eye region with Hounsfield Units (HU) of 140, 
corresponding to PLA  printed density of 1.12 g/cc. This bolus 
was exported from Eclipse and converted in STL file. Bolus 
creation and printing took approximately 1 hour. To verify 
the form of the 3D-printed bolus, its HU, and dose 
distribution obtained when using it, the latter was positioned 
on the head phantom and a CT scan was acquired.  Two plans 
with anterior-posterior fields and 6 MV X-ray beams were 
created using either the “digital” or the 3D-printed bolus and 
plans were compared. To measure and compare the dose 
distribution, skin layers of 3 mm and 5 mm thickness were 
created, just beneath the bolus, as well as a target 
simulating a tumor reaching the body surface (see figure). 
The analytical anisotropic algorithm was used for dose 
calculation with a grid size of 1 mm.  
Results: The first 3D-printed bolus contained some air 
bubbles, and had a smaller thickness (less than 0.1 cm) but 
properly reproduced the form (see figure). The printed bolus 
presented in its solid portion a density of 140-150 HU with 
values as low as ≈-450 HU in the bubble regions  and a mean 
±SD value of -32 ± 154 HU. Dosimetric comparison showed 
good agreement on mean doses and max doses, while 
volumes receiving 95% of the prescribed dose differed by ≈6% 
for all structures with 3D-printed bolus plans showing more 
coverage, (see table).  
Conclusion: In conclusion, first dosimetric results look 
promising and further tests will be implemented to improve 
the bolus filling and the erosion of the surface, as well as to 
investigate the possibility to use soft PLA materials (likely 
more comfortable for patients). More sophisticated, realistic 
patient’s plans should be tested and in-vivo thermo 
luminescent dosimetry should be used for treatment plan 
verification. 
 
